Ginkgo Bioworks has been granted a patent for gene therapy compositions using Adeno-associated virus (AAV) vectors to treat NPC1. The patent includes a specific AAV vector design with a sequence of capsid protein subunit and a transfer cassette encoding NPC1 protein. GlobalData’s report on Ginkgo Bioworks gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Ginkgo Bioworks Holdings Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Ginkgo Bioworks, was a key innovation area identified from patents. Ginkgo Bioworks's grant share as of April 2024 was 25%. Grant share is based on the ratio of number of grants to total number of patents.

Gene therapy composition for treating npc1 using aav vectors

Source: United States Patent and Trademark Office (USPTO). Credit: Ginkgo Bioworks Holdings Inc

A recently granted patent (Publication Number: US11905523B2) discloses an adeno-associated virus (AAV) vector designed for gene therapy applications. The vector includes a protein capsid with a specific capsid protein subunit sequence and a nucleic acid containing a transfer cassette. The transfer cassette consists of various elements, including inverted terminal repeats, a promoter, a transgene encoding a Niemann-Pick intracellular cholesterol transporter 1 (NPC1) protein, a polyadenylation signal, and more. Additionally, the vector may contain an intronic sequence and an enhancer to enhance its therapeutic efficacy.

Furthermore, the patent covers the use of this AAV vector in compositions, cells, and methods for treating individuals with Neimann-Pick Disease Type C. By administering an effective amount of the AAV vector to a subject in need, particularly human subjects, the method aims to address the genetic disorder by delivering the NPC1 protein-encoding transgene. The inclusion of specific sequences and elements in the vector, as outlined in the claims, ensures the targeted and efficient delivery of the therapeutic gene for potential clinical applications in treating this rare genetic condition.

To know more about GlobalData’s detailed insights on Ginkgo Bioworks, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies